Simvastatin reduces portal hypertension in HCV-cirrhotic patients, as proved by significant reduction of portal vein congestion index.Its use is relatively safe in patients with compensated cirrhosis.However, it has no direct beneficial effect on endoscopic features of portal hypertension.It doesn't affect the serum level of eNOS, so this should not be used as a serum marker for monitoring the eff...
Simvastatin reduces portal hypertension in HCV-cirrhotic patients, as proved by significant reduction of portal vein congestion index.Its use is relatively safe in patients with compensated cirrhosis.However, it has no direct beneficial effect on endoscopic features of portal hypertension.It doesn't affect the serum level of eNOS, so this should not be used as a serum marker for monitoring the eff...